Press release
- This press release from 21 March 2008 refers to a publication by Deras et al. which was published in the peer-reviewed Journal of Urology.
- This study confirms that the PROGENSATM PCA3 Assay, the world’s first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide prostate cancer diagnosis.
- Dr. Jack Groskopf, director of Oncology Research and Development at Gen-Probe Incorporated and co-author of the study, commented: "We found that the percent of biopsy-positive men identified directly increased with the PCA3 Score. We also confirmed that the PCA3 Score was independent of prostate size; this is important because prostate specific antigen (PSA) levels can be elevated in men who have enlarged prostates due to non-cancerous conditions. The PROGENSA PCA3 Assay provides physicians with valuable information to guide biopsy decisions."
More information; Article at The Medical News